Analogues of PYY

A method of treating obesity, reducing appetite, reducing food intake, or reducing calorie intake in a subject, comprising:

• administering to a subject in need thereof a therapeutically effective amount of
• a) an analogue of PYY which differs from the sequence of native human PYY (SEQ ID NO:
• 1) in the following respects:
• i) Ser23 is substituted with Ala23, Glu23, or Aib23,
• ii) Asn18 is substituted with Leu18, Aib18 or Ala18, and
• iii) the analogue of PYY further differs from the sequence of native human PYY in at least one of the following respects:
• Tyr1 is absent,
• Glu10 is substituted with Lys10 or Gln10,
• Asp11 is substituted with Gly11,
• Arg19 is substituted with His19,
• Tyr27 is substituted with Phe27,
• Leu30 is substituted with His30, and
• Val31 is substituted with Leu31,
• wherein
• Lys4 is not substituted, and
• the C-terminal residue optionally terminates in a primary amide group (—C(O)NH2) in place of a carboxylic acid group (—CO2H);
• or
• b) a derivative of the analogue, wherein the derivative is selected from the group consisting of amidation, glycosylation, carbamylation, acylation, sulfation, phosphorylation, cyclization, lipidization, PEGylation, and fusion to another peptide or to a protein to form a fusion protein, or
• c) a salt or solvate of the analogue or the derivative of the analogue.